Earnings Report(Kessan Tanshin) Presentation Quarterly Financial Report Webcast Excel version of selected tables from the Quarterly Financial Report Quarterly Highlights Infographic By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze...
Financial Highlights Quarterly Results Stock Information & Shareholder Returns Securities Report & Form 20-F IR Events FY2024 (April 2024-March 2025) Quarter 3 Earnings Report(Kessan Tanshin) Presentation Quarterly Financial Report Webcast Excel version of selected tables from the Quarterly Financial ...
Explore Takeda's 2024 Annual Integrated Report showcasing our dedication to global health and a brighter future. Discover our corporate philosophy, sustainable value creation, and innovative biopharmaceutical approaches.
Takeda also announced today its decision to buy back shares up to JPY 100.0 billion, underscoring confidence in its strong business momentum and commitment to shareholder returns. For details, see release: Takeda Announces Acquisition of Own Shares Takeda chief financial officer, Milano Furuta, comment...
(NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024, provided an update on its recent corporate activities and reiterated its 2025 financial guidance. "I am excited to announce that the ...
Costa Saroukos, Chief Financial Officer, Takeda, said, “This announcement continues Takeda’s strong momentum toward optimizing our portfolio for growth by delivering highly-innovative medicines and transformative care in our chosen business areas, as well as meeting our leverage targets. As we contin...
Takeda is continuing to assess the financial impacts of the study results, including impairment loss for intangible assets, on the first quarter ending June 30, 2024 and will communicate as necessary in due course. About Soticlestat (TAK-935) ...
Takeda and Protagonist Therapeutics, Inc., announced the signing of a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural...
Get Takeda Pharmaceutical Co Ltd (TAK:NYSE) real-time stock quotes, news, price and financial information from CNBC.
Takeda’s global operations are organized into five main areas: the U.S., Japan, China, Europe with Canada, and an additional group known as Growth & Emerging Markets encompassing close to 80 countries. Within this framework, Europe’s value goes beyond financial contributions; it is central ...